Orexin receptor antagonists – a patent review (2010 to August 2014)

Bibliography

• Gatfield J, Brisbare-Roch C, Jenck F, et al. Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 2010;5:1197-214
   PubMed Web of Science ®Google Scholar
• deLecca L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-7
   Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85
   PubMed Web of Science ®Google Scholar
• Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52:891-903
   PubMed Web of Science ®Google Scholar
• Matsuki T, Sakurai T. Orexins and orexin receptors: from molecules to integrative physiology. Results Probl Cell Differ 2008;46:27-55
   PubMedGoogle Scholar
• Randeva HS, Karteris E, Grammatopoulos D, et al. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J Clin Endocrinol Metab 2001;86:4808-13
   Google Scholar
• Nilaweera KN, Barrett P, Mercer JG, Morgan PJ. Precursor-protein convertase 1 gene expression in the mouse hypothalamus: differential regulation by ob gene mutation, energy deficit and administration of leptin, and coexpression with prepro-orexin. Neuroscience 2003;119:713-20
   Google Scholar
• Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015
   PubMed Web of Science ®Google Scholar
• Marcus JN, Aeschkenasi CE, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6-25
   PubMed Web of Science ®Google Scholar
• Mieda M, Hasegawa E, Kisanuki YY, et al. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 2011;31:6518-26
   PubMed Web of Science ®Google Scholar
• Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
   PubMed Web of Science ®Google Scholar
• Cheminelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51
   Google Scholar
• Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38:715-30
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40
   PubMed Web of Science ®Google Scholar
• Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62
   PubMed Web of Science ®Google Scholar
• Smith MI, Piper DC, Duxon MS, et al. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci Lett 2003;341:256-8
   PubMed Web of Science ®Google Scholar
• Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5
   PubMed Web of Science ®Google Scholar
• Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Schreier JD, Cox CD, et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012;7:415-24
   PubMed Web of Science ®Google Scholar
• Boss C, Brisbare-Roch C, Jenck F, et al. Orexin receptor antagonism: a new principle in neuroscience Chimia. 2008;62:974-9
   Google Scholar
• Dingemanse J, Dorffner G, Hajak G, et al. Proof-of-concept study in primary insomnia patients with ACT-078573, a dual orexin receptor antagonist (Abstract). Sleep Biol Rhythms 2007;5:A194
   Google Scholar
• Neubauer DN. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Invest Drugs 2010;11:101-10
   Google Scholar
• Dugovic C, Shelton J, Sutton S, et al. Sleep-inducing effects mediated by selective blockade of orexin OX2 receptors during the light phase in the rat (Abstract). Sleep 2008;31:A33
   Google Scholar
• Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330:142-51
   PubMed Web of Science ®Google Scholar
• Etori K, Saito Y C, Tsujino N. Sakurai, T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front Neurosci 2014;8:8-1-13
   PubMedGoogle Scholar
• Yamanaka T, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regu- late arousal according to energy balance in mice. Neuron 2003;38:701-13
   PubMed Web of Science ®Google Scholar
• Sakurai T. Orexin: a link between energy homeostasis and adaptive behaviour. Curr Opin Clin Nutr Metab Care 2003;6:353-60
   PubMed Web of Science ®Google Scholar
• Berthoud HR. Mind versus metabolism in the control of food intake and energy balance. Physiol Behav 2004;81:781-93
   Google Scholar
• Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006;443:289-95
   PubMed Web of Science ®Google Scholar
• Siegel JM, Boehmer LN. Narcolepsy and the hypocretin system–where motion meets emotion. Nat Clin Pract Neurol 2006;2:548-56
   PubMedGoogle Scholar
• Geerling JC, Mettenleiter TC, Loewy AD. Orexin neurons project to diverse sympathetic outflow systems. Neuroscience 2003;122:541-50
   Google Scholar
• Zhang W, Sakurai T, Fukuda Y, et al. Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. Regul Integr Comp Physiol 2006;290:R1654-63
   Google Scholar
• Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med 2010;16:111-15
   PubMed Web of Science ®Google Scholar
• Aston-Jones G, Smith RJ, Sartor GC, et al. Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res 2010;1314:74-90
   PubMed Web of Science ®Google Scholar
• Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005;437:556-9
   PubMed Web of Science ®Google Scholar
• Steiner MA, Gatfield J, Brisbare-Roch C, et al. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 2013;8:898-903
   PubMed Web of Science ®Google Scholar
• Heinonen MV, Purhonen AK, Makela KA, et al. Functions of orexins in peripheral tissues. Acta Physiol 2008;192:471-85
   PubMed Web of Science ®Google Scholar
• Malherbe P, Borroni E, Pinard E, et al. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol 2009;76(3):618-31
   Google Scholar
• Dugovic C, Shelton JE, Leah E A, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;1):142-51
   Google Scholar
• Di Fabio R; Glaxo Group Limited. WO2011023585; 2011
   Google Scholar
• Di Fabio R; Glaxo Group Limited. WO2011023578; 2011
   Google Scholar
• Alvaro G, Amantini D; Glaxo Group Limited. WO2010072722; 2010
   Google Scholar
• Alvaro G, Amantini D, Belvedere S; Glaxo Group Limited. WO2010060472; 2010
   Google Scholar
• Alvaro G, Amantini D, Belvedere S; Glaxo Group Limited. WO2010060470; 2010
   Google Scholar
• Alvaro G, Amantini D, Belvedere S; Glaxo Group Limited. WO2010060471; 2010
   Google Scholar
• Alvaro G, Amantini D, Castiglioni E, et al. Glaxo Group Limited. WO2010063663; 2010
   Google Scholar
• Di Fabio R; Glaxo Group Limited. WO2012089606; 2012
   Google Scholar
• Alvaro G, Amantini D, Castiglioni E, et al. Glaxo Group Limited. WO2010063662; 2010
   Google Scholar
• Amantini D, Di Fabio R; Glaxo Group Limited. WO2010122151; 2010
   Google Scholar
• Di Fabio R; Glaxo Group Limited. WO2012089607; 2012
   Google Scholar
• Behnke D, Betschart C, Cotesta S, et al. Novartis AG. WO2011073316; 2011
   Google Scholar
• Behnke D, Betschart C, Cotesta S, et al. Novartis AG. WO2010086366; 2010
   Google Scholar
• Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2011076744,2011
   Google Scholar
• Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2012055888; 2012
   Google Scholar
• Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2011076747; 2011
   Google Scholar
• Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2012101487; 2012
   Google Scholar
• Betschart C, Hintermann S, Behnke D, et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 2013;56:7590-607
   PubMedGoogle Scholar
• Cox CD, Fraley ME, Schreier J; Merck Sharp & Dohme Corp. WO2010048017; 2010
   Google Scholar
• Breslin MJ, Coleman PJ, Cox CD, et al. Merck Sharp & Dohme Corp. WO2010048010; 2010
   Google Scholar
• Cox CD, Coleman PJ, Breslin MJ, et al. Merck Sharp & Dohme Corp. WO2010048012; 2010
   Google Scholar
• Cox CD, Coleman P J, Flores B, et al. Merck Sharp & Dohme Corp. WO2010048013; 2010
   Google Scholar
• Kuduk SD, Skudlarek J W; Merck Sharp & Dohme Corp. WO2013059222; 2013
   Google Scholar
• Cox CD, Coleman OJ, Schreier JD; Merck Sharp & Dohme Corp. WO2010048014; 2010
   Google Scholar
• Cox CD, Flores B, Schreier JD; Merck Sharp & Dohme Corp. WO2010048016; 2010
   Google Scholar
• Kuduk SD, Di Marco C; Merck Sharp & Dohme Corp. WO2013059163; 2013
   Google Scholar
• Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2013062857; 2013
   Google Scholar
• Kuduk SD, Skudlarek JW, Di Marco CN, et al. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorg Med Chem Lett 2014;24:1784-9
   Google Scholar
• Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014062533; 2014
   Google Scholar
• Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014066196; 2014
   Google Scholar
• Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014085208; 2014
   Google Scholar
• Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014099696; 2014
   Google Scholar
• Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014099697; 2014
   Google Scholar
• Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014099698, 2014
   Google Scholar
• Kuduk SD, Cooke A, Stump C; Merck Sharp & Dohme Corp. WO2014113303, 2014
   Google Scholar
• Branstetter BJ, Letavic MA, Ly KS, et al. Janssen Pharmaceutica NV. WO2011050200, 2011
   Google Scholar
• Roecker AJ, Mercer SP, Schreier JD, et al. Discovery of 5’’-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2’:5’,3’’-terpyridine-3’-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22
   PubMed Web of Science ®Google Scholar
• Roecker AJ, Reger TS, Mattern MC, et al. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90
   Google Scholar
• Coleman PJ, Mercer SP, Reger TS, et al. Merck Sharp & Dohme Corp. WO2010017260, 2010
   Google Scholar
• Bergman JM, Coleman PJ, Mattern MC, et al. Merck Sharp & Dohme Corp. WO2010051236, 2010
   Google Scholar
• Bergman JM, Coleman PJ, Roecker AJ, et al. Merck Sharp & Dohme Corp. WO2010051237, 2010
   Google Scholar
• Coleman PJ, Cox CD, Mercer SP, et al. Merck Sharp & Dohme Corp. WO2010051238, 2010
   Google Scholar
• Mercer SP, Roecker AJ; Merck Sharp & Dohme Corp. WO2010141275, 2010
   Google Scholar
• Mercer SP, Roecker AJ; Merck Sharp & Dohme Corp. WO2011005636, 2011
   Google Scholar
• Li D, Roecker AJ; Merck Sharp & Dohme Corp. WO2013062858; 2013
   Google Scholar
• Coleman PJ, Mercer SP, Roecker AJ; Merck Sharp & Dohme Corp. WO2011053522, 2011
   Google Scholar
• Chai W, Letavic M A, Ly K S, et al. Janssen Pharmaceutica NV. WO2011050198; 2011
   Google Scholar
• Letavic MA, Rudolph DA, Savall BM, et al. Janssen Pharmaceutica NV. WO2012145581; 2012
   Google Scholar
• Branstetter BJ, Letavic MA, Ly KS, et al. Janssen Pharmaceutica NV. WO2011050202; 2011
   Google Scholar
• Terauchi T, Takemura A, Doko T, et al. Eisai R & D Management Co., Ltd. WO2012039371; 2012
   Google Scholar
• Oi N, Suzuki M, Terauchi T, et al. Synthesis and evaluation of novel radioligands for positron emission tomography imaging of the orexin-2 receptor. J Med Chem 2013;56:6371-85
   Google Scholar
• Nozawa D, Suzuki R, Futamura A, et al. Taisho Pharmaceutical Co. WO2012081692; 2012
   Google Scholar
• Suzuki R, Futamura A, Abe M, et al. Taisho Pharmaceutical Co. WO2012153729; 2012
   Google Scholar
• Araki Y, Nozawa D, Zuki R, et al. Taisho Pharmaceutical Co. WO2013187466; 2013
   Google Scholar
• Futamura A, Araki Y, Abe M, et al. Taisho Pharmaceutical Co. WO2013187467; 2013
   Google Scholar
• Abe M, Futamura A, Suzuki R, et al. Taisho Pharmaceutical Co. WO2013005755; 2013
   Google Scholar
• Ohta H, Abe M; Taisho Pharmaceutical Co. WO2014091876; 2014
   Google Scholar
• Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010044054; 2010
   Google Scholar
• Bentley JM, Davenport T, Slack M, Evotec AG. WO2011138265; 2011
   Google Scholar
• Bentley JM, Davenport T, Hallett DJ, Evotec AG. WO2011138266; 2011
   Google Scholar
• Knust H, Nettekoven M, Pinard E, et al. F. Hoffmann-La Roche AG. WO2010012620; 2010
   Google Scholar
• Bingham MJ, Dunbar NA, Huggett M J, et al. N.V. Organon. WO2011061318; 2011
   Google Scholar
• Kamenecka T, Jiang R, Song X; Eolas Therapeutics Inc. WO2013119639; 2013
   Google Scholar
• Aissaoui H, Boss C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2009016560; 2009
   Google Scholar
• Aissaoui H, Boss C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2009016564; 2009
   Google Scholar
• Aissaoui H, Boss C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2009004584; 2009
   Google Scholar
• Branch CL, Nash DJ, Stemp G; GlaxoSmith Kline. WO2003051368; 2003
   Google Scholar
• Drahl C. To dream, perchance of sleep. Chem Eng News 2014;92(35):52-5
   Google Scholar
• Congreve MS, Christopher JA, Tehan BG, et al. WO2014006402; 2014
   Google Scholar
• Stasi LP, Rovati L; Rottapharm S.P.A. WO2011006960; 2011
   Google Scholar
• Stasi LP, Rovati LC, Artusi R, et al. Rottapharm S.P.A. WO2013092893; 2013
   Google Scholar
• Stasi LP, Rovati L; Rottapharm S.P.A. WO2013139730; 2013
   Google Scholar
• Stasi LP, Rovati L, Artusi R, et al. Rottapharm S.P.A. WO2013127913; 2013
   Google Scholar
• Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010038200; 2010
   Google Scholar
• Aissaoui H, Boss C, Hazemann J, et al. Actelion Pharmaceuticals Ltd. WO2010004507; 2010
   Google Scholar
• Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010131191; 2010
   Google Scholar
• Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010131192; 2010
   Google Scholar
• Aissaoui H, Boss C, Brotshci C, et al. Actelion Pharmaceuticals Ltd. WO2012063207; 2012
   Google Scholar
• Sifferlen T, Boller A, Chardonneau A, et al. Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1. Bioorg Med Chem Lett 2014;24:1201-8
   PubMed Web of Science ®Google Scholar
• Boss C, Brotschi C, Gatfield J, et al. Actelion Pharmaceuticals Ltd. WO2012025877; 2012
   Google Scholar
• Hoch M, va Gorsel H, van Greven J, Dingemanse J. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant. J Clin Pharm 2014;54(9):979-86
   PubMed Web of Science ®Google Scholar
• Boss C, Roch-Brisbare C, Steiner MA, et al. Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist. ChemMedChem 2014;9. [Epub ahead of print]
   Google Scholar
• Boss C, Brotschi C, Heidmann B, et al. Actelion Pharmaceuticals Ltd. WO2012085852; 2012
   Google Scholar
• Boss C, Brotschi C, Heidmann B, et al. Actelion Pharmaceuticals Ltd. WO2012085857; 2012
   Google Scholar
• Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2012110986; 2012
   Google Scholar
• Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2012114252; 2012
   Google Scholar
• Boss C, Brotschi C, Heidmann B, et al. Actelion Pharmaceuticals Ltd. WO2013050938; 2013
   Google Scholar
• Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2013068935; 2013
   Google Scholar
• Boss C, Brotschi C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2013182972; 2013
   Google Scholar
• Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2014057435; 2014
   Google Scholar